

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,421	06/24/2005	Shinya Yoshida	Q88668	4181
65565 SUGHRUE-26	7590 03/21/2008 55550		EXAM	IINER
2100 PENNSYLVANIA AVE. NW WASHINGTON, DC 20037-3213			ROBINSON, BINTA M	
			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			03/21/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) YOSHIDA ET AL 10/5/10 /21

	10/340,421	TOSHIDA ET AL.				
Office Action Summary	Examiner	Art Unit				
	BINTA M. ROBINSON	1625				
The MAILING DATE of this communication app	ears on the cover sheet with the o	correspondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILURD D Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the soft or returned for or pely with 12 child. Any reply received by the Office later than three months after the mailing earned patent term dejurement. See 37 CFR 1.7(4p).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nety filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
Responsive to communication(s) filed on						
2a)☐ This action is FINAL . 2b)⊠ This action is non-final.						
3) Since this application is in condition for allowar	nce except for formal matters, pro	secution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Plan a Man of Olahan						
Disposition of Claims						
4)⊠ Claim(s) <u>1-7</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-7</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)⊡ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)☐ Some * c)☐ None of:						
1. Certified copies of the priority documents have been received.						
Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau	(PCT Rule 17.2(a)).	-				
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate				
3) Notice of Informal Patent Application Paper No(s) Mail Date 10/12/05. 13) Notice of Informal Patent Application Paper No(s) Mail Date 10/12/05. 14) Other:						
	6) L. Oulei					

Page 2

Application/Control Number: 10/540,421

Art Unit: 1625

Detailed Action

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- Claims 1-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter
- which applicant regards as the invention.
- A. In claim 1, line 3, and all other occurrences throughout claims 2-5 the phrase "ester residue" is indefinite, because the actual structures that these structures can represent are not delineated in the specification and it is unclear what "structure".
- Regarding claims 4, 5, 6, 7, the phrase "if necessary" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. Claims 1-5 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for ethyl esters, does not reasonably provide enablement for all ester residues. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The claim(s) contains

Application/Control Number: 10/540,421

Art Unit: 1625

subject matter, which was not described in the specification in such a way as to enable one skilled in the art of medicinal chemistry to use the invention. "The factors to be considered [in making an enablement rejection] have been summarized as a) the quantity of experimentation necessary, b) the amount of direction or guidance presented, c) the presence or absence of working examples, d) the nature of the invention, e) the state of the prior art, f) the relative skill of those in that art, q) the predictability or unpredictability of the art, h) and the breadth of the claims", In re Rainer, 146 USPQ 218 (1965); In re Colianni, 195 USPQ 150, Ex parte Formal, 230 USPQ 546. a) Finding a prodrug is an empirical exercise. Predicting what compounds of formula I will result when R1 is a certain ester residue is filled with experimental uncertainty, since it is not even clear if esters are being claimed or some derivative thereof. b) The direction concerning esters is found at page 6, line 11, page 6, which states that "with regard to "ester residue in R1, any group may be used so far as it is a group which is able to be converted to HO-(C=O)-by a reaction for removal of R1 from R1O-(C=O). The specific groups that the ester residue can be, are not delineated c) There is are only working examples of ethyl esters. d) The nature of the invention is use of these compounds of

Page 4

Application/Control Number: 10/540,421

Art Unit: 1625

formula I wherein R1 may be an ester residue as intermediates in the synthesis of a final product. g) It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved", and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). h) The breadth of the claims includes all of the hundreds of thousands of compounds of formula I as well as the presently unknown list of potential ester residues of said compounds.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Binta M. Robinson whose telephone number is (571) 272-0692. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Janet Andres can be reached on 571-272-0670.

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine are (703)308-4242, (703305-3592, and (703305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

/JANET L. ANDRES/ Supervisory Patent Examiner, Art Unit 1625